InsidersTradesSigma
Follow the Edgewise Therapeutics, Inc. stock price and the full management transaction log of the company, a listed equity based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Edgewise Therapeutics, Inc. has published 121 public disclosures. Market capitalisation: €4.3bn. The latest transaction was reported on 14 August 2026 (Levée d'options). Among the most active insiders: Russell Alan J. Every trade is free.
121
Insider Decl.
n/a
Thresholds
€40m
11 ops.
Buy Volume
€6m
36 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Edgewise Therapeutics, Inc. Strong Buy (bullish), based on 13 analysts. Average price target: US$49.92.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 14 August 2026
Declarations121 total
5,781 shares0Common StockSEC:0001853109-26-000001:0
7,500 shares0Common StockSEC:0001853109-26-000001:1
2,171 shares@ US$43.7934Common StockSEC:0001853109-26-000001:2
304 shares@ US$44.5018Common StockSEC:0001853109-26-000001:3
150 shares@ US$44.4433Common StockSEC:0001853109-26-000001:4
2,475 shares@ US$43.6984Common StockSEC:0001853109-26-000001:5
5,781 shares0Common StockSEC:0001644087-26-000005:0
7,031 shares0Common StockSEC:0001644087-26-000005:1
2,839 shares@ US$43.784Common StockSEC:0001644087-26-000005:2
2,779 shares@ US$43.7073Common StockSEC:0001644087-26-000005:3
104 shares@ US$44.4253Common StockSEC:0001644087-26-000005:4
800 shares@ US$44.5175Common StockSEC:0001644087-26-000005:5
2,919 shares@ US$43.4065Common StockSEC:0001644087-26-000005:6
17,969 shares0Common StockSEC:0001185829-26-000001:0
21,875 shares0Common StockSEC:0001185829-26-000001:1
8,782 shares@ US$43.6408Common StockSEC:0001185829-26-000001:2
8,276 shares@ US$43.6582Common StockSEC:0001185829-26-000001:3
913 shares@ US$44.33Common StockSEC:0001185829-26-000001:4
5,781 shares0Common StockSEC:0001191702-26-000001:0
6,718 shares0Common StockSEC:0001191702-26-000001:1
2,439 shares@ US$43.8081Common StockSEC:0001191702-26-000001:2
59 shares@ US$44.4142Common StockSEC:0001191702-26-000001:3
99 shares@ US$44.5019Common StockSEC:0001191702-26-000001:4
2,419 shares@ US$43.7985Common StockSEC:0001191702-26-000001:5
5,781 shares0Common StockSEC:0001853529-26-000002:0
25 of 121 declarations
About Edgewise Therapeutics, Inc.
Recent highlights include Edgewise’s early-May 2026 first-quarter financial update and clinical progress report in muscular dystrophy and cardiovascular programs. The company also outlined 2026 corporate priorities and announced participation in a RBC Capital Markets healthcare conference in May 2026. In the context of SEC Form 4 insider filings, investors should interpret insider transactions carefully, as they often reflect equity compensation or prearranged 10b5-1 plans rather than a standalone fundamental signal. Overall, Edgewise remains a specialty biotech name with meaningful scientific optionality, but also a high-risk profile typical of clinical-stage companies.
